China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
Venture

9 Nov 2026China VenturesPr newswire

Sanyou Bio closes exclusive Series C, lifting total funding to nearly RMB300m

Sanyou Bio has closed an exclusive Series C from Zero2IPO Industry Investment, bringing total funding to nearly RMB300m as it builds an AI-driven drug-discovery platform.

Sanyou Bio closes exclusive Series C, lifting total funding to nearly RMB300m
Image: China Ventures

What happened

Sanyou Bio closed an exclusive Series C from Zero2IPO Industry Investment, taking total funding to nearly RMB300m. The company describes the capital as backing an AI-driven ecosystem for innovative drug discovery and translation. It is a single strategic investor, not a syndicate, and terms were not disclosed.

The numbers

  • Round: exclusive Series C.
  • Investor: Zero2IPO Industry Investment.
  • Total raised: nearly RMB300m.
  • Terms: not disclosed.

Why it matters

Antibody and protein discovery services in China are consolidating around platforms that pair AI design with wet-lab validation. A strategic investor can bring customers, data and licensing introductions, which matters more to a services business than a higher headline price.

The counter-argument is that an exclusive round concentrates influence in one shareholder and can narrow the company's options if it later needs a large syndicate. Without terms, it is also unclear how much of the nearly RMB300m is equity and how much is structured. The strategic logic, however, is clear: capital is moving into discovery platforms ahead of the next licensing cycle.

What to watch

  • The commercial terms behind the exclusive arrangement.
  • Sanyou's licensing pipeline and any pharma partnerships.
  • Whether Zero2IPO introduces portfolio companies as customers.

Original source: Manila Times · 9 Nov 2026

All insights ↗